Filter Results:
(168)
Show Results For
- All HBS Web
(1,063)
- Faculty Publications (168)
Show Results For
- All HBS Web
(1,063)
- Faculty Publications (168)
- January 2009 (Revised February 2009)
- Case
Sydney IVF: Stem Cell Research
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
This case examines the strategy implementation and risk management decisions at Sydney IVF, a research-based in vitro fertilization and stem cell company based in Australia. Drs. Robert Jansen and Jock Anderson, who co-founded Sydney IVF in 1986, developed novel... View Details
Keywords: Ethics; Governing Rules, Regulations, and Reforms; Innovation and Management; Growth and Development Strategy; Risk Management; Genetics; Commercialization; Health Industry; Australia
Simons, Robert L., Kathryn Rosenberg, and Natalie Kindred. "Sydney IVF: Stem Cell Research." Harvard Business School Case 109-017, January 2009. (Revised February 2009.)
- October 2008
- Case
Diagnostic Genomics
By: Regina E. Herzlinger and Mark P. Allyn
Should this gene detection firm enter the business of providing tests for the detection of genetic diseases? If so, how should it prioritize the tests it could develop? View Details
Keywords: Health Testing and Trials; Market Entry and Exit; Product Development; Genetics; Strategy; Health Industry; Health Industry
Herzlinger, Regina E., and Mark P. Allyn. "Diagnostic Genomics." Harvard Business School Case 309-040, October 2008.
- September 2008
- Background Note
Background on the Technology of Molecular Diagnostics
By: Regina E. Herzlinger and Jason Sanders
To be used as background reading for the "EXACT Sciences Corp.: Commercializing a Diagnostic Test" and "Diagnostic Genomics" cases, HBS nos. 308-090 and 309-040. View Details
Keywords: Health Testing and Trials; Technology; Medical Devices and Supplies Industry; Medical Devices and Supplies Industry
Herzlinger, Regina E., and Jason Sanders. "Background on the Technology of Molecular Diagnostics." Harvard Business School Background Note 309-050, September 2008.
- February 2008 (Revised August 2008)
- Case
EXACT Sciences Corp.: Commercializing a Diagnostic Test
This case addresses the challenges of commercializing molecular diagnostics. Along the way, it explains the technology, payment system, and the measures used to assess the value of a diagnostic test. View Details
Keywords: Health Testing and Trials; Genetics; Science-Based Business; Commercialization; Biotechnology Industry
Herzlinger, Regina E. "EXACT Sciences Corp.: Commercializing a Diagnostic Test." Harvard Business School Case 308-090, February 2008. (Revised August 2008.)
- February 2008
- Article
Does Focus Improve Operational Performance? Lessons from the Management of Clinical Trials
By: Robert S. Huckman and Darren Zinner
Huckman, Robert S., and Darren Zinner. "Does Focus Improve Operational Performance? Lessons from the Management of Clinical Trials." Strategic Management Journal 29, no. 2 (February 2008): 173–193.
- Article
Financial Incentive Based Approaches for Weight Loss: A Randomized Trial
By: Kevin Volpp, Leslie K. John, Andrea Troxel, Laurie Norton, Jennifer Fassbender and George Loewenstein
Volpp, Kevin, Leslie K. John, Andrea Troxel, Laurie Norton, Jennifer Fassbender, and George Loewenstein. "Financial Incentive Based Approaches for Weight Loss: A Randomized Trial." JAMA, the Journal of the American Medical Association 300, no. 22 (December 10, 2008): 2631–2637.
- 2007
- Book
Mergers: Leadership, Performance & Corporate Health
By: David G. Fubini, Colin Price and Maurizio Zollo
Drawing on their own extensive integration experience, the systematic analysis of 167 mergers, and cutting edge academic research, the authors of this book identify the common leadership challenges to be tackled for the achievement of what we call 'corporate health',... View Details
Keywords: Corporate Health; Mergers and Acquisitions; Leadership; Organizational Change and Adaptation; Success
Fubini, David G., Colin Price, and Maurizio Zollo. Mergers: Leadership, Performance & Corporate Health. Palgrave Macmillan, 2007.
- November 2007
- Case
Antegren: A Beacon of Hope
By: Joshua D. Margolis, Thomas J. DeLong and Terence Heymann
The CEO of Biogen Idec faces a set of difficult decisions regarding a promising drug for Multiple Sclerosis that is headed for early approval by the FDA. The first in a series focuses on operational decisions triggered by the drive for early approval. Sparks discussion... View Details
Keywords: Demand and Consumers; Leadership; Ethics; Corporate Social Responsibility and Impact; Decision Choices and Conditions; Crisis Management; Health Testing and Trials; Biotechnology Industry; Pharmaceutical Industry
Margolis, Joshua D., Thomas J. DeLong, and Terence Heymann. "Antegren: A Beacon of Hope." Harvard Business School Case 408-025, November 2007.
- June 2007
- Article
Efficient Kidney Exchange: Coincidence of Wants in a Structured Market
By: A. E. Roth, Tayfun Sonmez and M. Utku Unver
Patients needing kidney transplants may have donors who cannot donate to them because of blood or tissue incompatibility. Incompatible patient-donor pairs can exchange donor kidneys with other pairs only when there is a "double coincidence of wants." Developing... View Details
Keywords: Organizational Structure; Size; Emotions; Human Needs; Health Care and Treatment; Health Testing and Trials; Infrastructure; Supply Chain Management; Fairness; Performance Improvement; Health Industry
Roth, A. E., Tayfun Sonmez, and M. Utku Unver. "Efficient Kidney Exchange: Coincidence of Wants in a Structured Market." American Economic Review 97, no. 3 (June 2007): 828–851.
- October 2006 (Revised August 2007)
- Case
Calloway Laboratory: Pee for Profit
By: Richard G. Hamermesh and David Kiron
Describes the formation and rapid growth of a drug-testing company. The company needs to decide whether to enter the painkiller testing market, in addition to growing its drug treatment center business. View Details
Keywords: For-Profit Firms; Health Care and Treatment; Health Testing and Trials; Growth and Development Strategy; Market Entry and Exit; Health Industry
Hamermesh, Richard G., and David Kiron. "Calloway Laboratory: Pee for Profit." Harvard Business School Case 807-040, October 2006. (Revised August 2007.)
- January 2006 (Revised July 2006)
- Case
Drug Testing in Nigeria (A)
By: Debora L. Spar
In 1996, a meningitis epidemic swept across Nigeria. Thousands of children were struck and, lacking appropriate medicine, were liable to die from the disease. Doctors at Pfizer had an antibiotic that could probably save most of these children's lives. The drug was new,... View Details
Keywords: Risk and Uncertainty; Health Pandemics; Health Testing and Trials; Developing Countries and Economies; Pharmaceutical Industry; Nigeria
Spar, Debora L., and Adam Day. "Drug Testing in Nigeria (A)." Harvard Business School Case 706-033, January 2006. (Revised July 2006.)
- August 2005 (Revised December 2006)
- Case
Procter & Gamble: Electronic Data Capture and Clinical Trial Management
By: Robert S. Huckman and Mark J. Cotteleer
Considers whether the management of Procter & Gamble (P&G) Pharmaceuticals should adopt Web-based electronic data capture (EDC) as the default standard for the management of its clinical drug trials. Provides a detailed description of the existing paper-based process... View Details
Keywords: Health Testing and Trials; Internet and the Web; Information Technology; Adoption; Business Processes; Industry Structures; Technological Innovation; Service Operations; Pharmaceutical Industry; United States
Huckman, Robert S., and Mark J. Cotteleer. "Procter & Gamble: Electronic Data Capture and Clinical Trial Management." Harvard Business School Case 606-033, August 2005. (Revised December 2006.)
- November 2003 (Revised September 2008)
- Case
Circle Gastroenterology Products (A)
By: Regina E. Herzlinger and James Weber
A new, minimally invasive medical device has achieved only one-third of its budget. Was the problem one of marketing strategy, sales, reimbursement, and/or clinical trials? View Details
Keywords: Health Testing and Trials; Marketing Strategy; Product Marketing; Sales; Medical Devices and Supplies Industry
Herzlinger, Regina E., and James Weber. "Circle Gastroenterology Products (A)." Harvard Business School Case 304-052, November 2003. (Revised September 2008.)
- August 2003 (Revised August 2024)
- Case
Fighting the Battle of the Bulge—Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment
By: Regina E. Herzlinger and John McDonough
Many health care innovations appear successful; but fail. This is the first case in the Innovating Health Care course that investigates how to create successful health care innovations. It is part of the first module in the course. This module focuses on how to... View Details
Keywords: Three Pillars; Industry Analysis; Health Care and Treatment; Innovation and Invention; Innovation and Management; Medical Specialties; Health Industry
Herzlinger, Regina E., and John McDonough. "Fighting the Battle of the Bulge—Evaluating Do Good/Do Well Innovations in Morbid Obesity Treatment." Harvard Business School Case 304-009, August 2003. (Revised August 2024.)
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the... View Details
Keywords: Decision Making; Health Testing and Trials; Innovation and Invention; Markets; Distribution; Product Development; Production; Problems and Challenges; Research; Research and Development; Complexity; Biotechnology Industry; Pharmaceutical Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (A)." Harvard Business School Case 603-043, April 2003. (Revised October 2004.)
- December 2002
- Teaching Note
Abgenix and the XenoMouse (TN)
Teaching Note for (501-061). View Details
- January 2001
- Case
Abgenix and the XenoMouse
By: Robert J. Dolan
Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early 2000, the company's cancer has performed very well in animal testing and is moving to early stage human testing. Abgenix must decide whether to... View Details
Keywords: Product Development; Marketing Strategy; Health Testing and Trials; Risk and Uncertainty; Technological Innovation; Innovation Strategy; Science-Based Business; Biotechnology Industry
Dolan, Robert J. "Abgenix and the XenoMouse." Harvard Business School Case 501-061, January 2001.
- May 1999 (Revised July 2000)
- Teaching Note
Reading Rehabilitation Hospital: Implementing Patient-Focused Care TN
By: Jody H. Gittell and Sandra J. Sucher
Teaching Note for (9-898-172). A rewritten version of an earlier teaching note. View Details
- July 1998
- Supplement
Bell Atlantic in Union City
In this pioneering project to wire a school for the Internet and put computers in students' homes, Bell Atlantic combined its need for a beta site for a technology trial with the school reform efforts of the Union City, New Jersey public schools, under the leadership... View Details
Keywords: Business Model; Social Enterprise; Internet and the Web; Education; Business and Community Relations; Education Industry; New Jersey
Kanter, Rosabeth M. "Bell Atlantic in Union City." Harvard Business School Video Supplement 399-501, July 1998.
- 1996
- Chapter
The Determinants of Research Productivity in Ethical Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn